AIM: To investigate the prognostic value of CD44 variant 6 (CD44v6), a membranous adhesion molecule, in rectal cancer. METHODS: Altogether, 210 rectal cancer samples from 214 patients treated with short-course radiotherapy (RT, n = 90), long-course (chemo) RT (n = 53) or surgery alone (n = 71) were studied with immunohistochemistry for CD44v6. The extent and intensity of membranous and cytoplasmic CD44v6 staining, and the intratumoral membranous staining pattern, were analyzed. RESULTS: Membranous CD44v6 expression was seen in 84% and cytoplasmic expression in 81% of the cases. In 59% of the tumors with membranous CD44v6 expression, the staining pattern in the invasive front was determined as "front-positive" and in 41% as "front-negative". The latter pattern was associated with narrower circumferential margin (P = 0.01), infiltrative growth pattern (P < 0.001), and shorter disease-free survival in univariate survival analysis (P = 0.022) when compared to the "front-positive" tumors. CONCLUSION: The lack of membranous CD44v6 in the rectal cancer invasive front could be used as a method to identify patients at increased risk for recurrent disease.
AIM: To investigate the prognostic value of CD44 variant 6 (CD44v6), a membranous adhesion molecule, in rectal cancer. METHODS: Altogether, 210 rectal cancer samples from 214 patients treated with short-course radiotherapy (RT, n = 90), long-course (chemo) RT (n = 53) or surgery alone (n = 71) were studied with immunohistochemistry for CD44v6. The extent and intensity of membranous and cytoplasmic CD44v6 staining, and the intratumoral membranous staining pattern, were analyzed. RESULTS: Membranous CD44v6 expression was seen in 84% and cytoplasmic expression in 81% of the cases. In 59% of the tumors with membranous CD44v6 expression, the staining pattern in the invasive front was determined as "front-positive" and in 41% as "front-negative". The latter pattern was associated with narrower circumferential margin (P = 0.01), infiltrative growth pattern (P < 0.001), and shorter disease-free survival in univariate survival analysis (P = 0.022) when compared to the "front-positive" tumors. CONCLUSION: The lack of membranous CD44v6 in the rectal cancer invasive front could be used as a method to identify patients at increased risk for recurrent disease.
Authors: P Herrlich; H Morrison; J Sleeman; V Orian-Rousseau; H König; S Weg-Remers; H Ponta Journal: Ann N Y Acad Sci Date: 2000-06 Impact factor: 5.691
Authors: Iris D Nagtegaal; Corrie A M Marijnen; Elma Klein Kranenbarg; Adri Mulder-Stapel; Jo Hermans; Cornelis J H van de Velde; J Han J M van Krieken Journal: J Pathol Date: 2002-05 Impact factor: 7.996
Authors: Anthony E Rizzardi; Xiaotun Zhang; Rachel Isaksson Vogel; Suzanne Kolb; Milan S Geybels; Yuet-Kin Leung; Jonathan C Henriksen; Shuk-Mei Ho; Julianna Kwak; Janet L Stanford; Stephen C Schmechel Journal: Diagn Pathol Date: 2016-07-11 Impact factor: 2.644
Authors: Eva-Maria Birkman; Adam Elzagheid; Terhi Jokilehto; Tuulia Avoranta; Eija Korkeila; Jarmo Kulmala; Kari Syrjänen; Jukka Westermarck; Jari Sundström Journal: Cancer Med Date: 2018-02-14 Impact factor: 4.452